CLYYF News and Press, Celyad SA

2024-04-04 12:24:15 ET More on Celyad Oncology SA Financial information for Celyad Oncology SA Read the full article on Seeking Alpha For further details see: Celyad Oncology SA reports FY results

2023-11-09 12:24:39 ET More on Celyad Oncology SA Financial information for Celyad Oncology SA For further details see: Celyad Oncology SA reports Q3 results

2023-03-24 10:39:02 ET Celyad Oncology SA (CYAD) Q4 2022 Results Earnings Conference Call March 24, 2023, 08:00 AM ET Company Participants David Georges - Vice President of Finance and Administration Michel Lussier - Interim Chief Executive Officer Eytan Breman -...

Celyad Oncology SA (CYAD) Q2 2022 Earnings Conference Call August 5, 2022 8:00 A.M. ET Company Participants Sara Zelkovic - Director, Communications and Investor Relations Michel Lussier - Interim Chief Executive Officer Charlie Morris - Chief Medical Officer ...

Celyad Oncology SA (CYAD) Q4 2021 Earnings Conference Call March 25, 2022 08:00 ET CompanyParticipants Daniel Ferry - LifeSci Advisors Filippo Petti - Chief Executive Officer Charles Morris - Chief Medical Officer David Gilham - Chief Scientific Officer Conference Call Participants Raju Prasa...

The following slide deck was published by Celyad Oncology SA in conjunction with this event. For further details see: Celyad Oncology (CYAD) Presents 2021 American Society of Hematology Meeting Update - Slideshow

The following slide deck was published by Celyad Oncology SA in conjunction with this event. For further details see: Celyad Oncology (CYAD) Presents Corporate Update at EHA 2021 - Slideshow

Celyad Oncology SA (CYAD) Q4 2020 Earnings Conference Call March 25, 2021 8:00 AM ET Company Participants Filippo Petti – Chief Executive Officer David Gilham – Chief Scientific Officer, Frederic Lehmann – Vice President-Global Clinical Development & Medical Affairs, ...

The following slide deck was published by Celyad Oncology SA in conjunction with this event. For further details see: Celyad Oncology (CYAD) Investor Presentation - Slideshow

Gracell Biotechnologies has filed to raise $100 million in a U.S. IPO, although the final figure may vary. The firm is developing treatments for various cancers using a CAR-T approach. GRCL has produced very promising Phase 1 trial results for its lead candidate. For further...